GVK BIO to acquire US CRO Aragen Bioscience

Asia’s leading small-molecule contract research organization (CRO), GVK BIO, has reached agreement to acquire Aragen Bioscience, a privately held USA-based, preclinical CRO specializing in high-value biologics services.

India-based GVK BIO will acquire the capital stock of Aragen Bioscience. This deal enables GVK BIO to expand its service offering to a broader base of organizations and gives GVK BIO expertise in biologics services and a significant US presence. The acquisition provides Aragen with the ability to expand its service offerings, access to GVK BIO’s global sales force and access to new markets. This is GVK BIO’s first international acquisition; the financial details were not disclosed.

“As an increasing number of biotech and pharmaceutical companies focus on protein based therapeutics and biosimilars, the acquisition of Aragen Bioscience will strategically enhance GVK BIO’s ability to offer high quality R&D services to the industry from a seamless integrated platform,” said the Indian firm’s chairman DS Brar.